KRAS and pancreatic ductal adenocarcinoma: To address whether the effects observed in KRASG12V-transformed HEK-HT cells are recapitulated in cancer cell lines, PIP5K1A expression was reduced in human pancreatic ductal adenocarcinoma (PDAC) cell lines, given that KRAS is mutated in this cancer more than any other2–4,6, and the frank lack of therapeutics to treat this disease46.